Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience
Article first published online: 16 DEC 2010
© 2010 THE AUTHORS; BJU INTERNATIONAL © 2010 BJU INTERNATIONAL
Volume 108, Issue 4, pages 539–545, August 2011
How to Cite
Yafi, F. A., Aprikian, A. G., Chin, J. L., Fradet, Y., Izawa, J., Estey, E., Fairey, A., Rendon, R., Cagiannos, I., Lacombe, L., Lattouf, J.-B., Bell, D., Drachenberg, D. and Kassouf, W. (2011), Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU International, 108: 539–545. doi: 10.1111/j.1464-410X.2010.09912.x
- Issue published online: 28 JUL 2011
- Article first published online: 16 DEC 2010
- Accepted for publication 13 August 2010
- bladder cancer;
- radical cystectomy;
Study Type – Therapy (case series)
Level of Evidence 4
To evaluate data obtained from a large, multi-institutional, contemporary series of patients who underwent radical cystectomy (RC) in a universal healthcare system aiming to assess outcome and identify novel prognostic variables.
MATERIALS AND METHODS
Data were collected and pooled from 2287 patients treated with RC between 1998 and 2008 by urological oncologists from eight Canadian academic centres. Collected variables included various clinicopathological parameters, recurrence and death. Survival and prognostic variables were analyzed using the Kaplan-Meier method and Cox regression analysis.
The median age of patients was 68 years with a mean (median) follow-up time of 35 (29) months. The 30, 60 and 90-day postoperative mortality rates were 1.3%, 2.6% and 3.2%, respectively. The 5-year overall, recurrence-free and cancer-specific survival was 57%, 48% and 67%, respectively, with a local recurrence rate of 6%. Pathological stage distribution was <pT2N0, n= 498 (23%); pT2N0, n= 365 (17%); pT3N0, n= 463 (21%); pT4N0, n= 170 (8%); and pTxN+, n= 507 (23%). Only 3.1% of patients received neoadjuvant chemotherapy and 19.4% received adjuvant chemotherapy. On multivariate analysis, lower pathological stage, negative surgical margins, receipt of adjuvant chemotherapy, performance of pelvic lymphadenectomy and an absence of smoking were associated with prolonged disease-specific and overall survival.
RC performed at academic centres provides excellent local control of disease and an acceptable clinical outcome with low perioperative mortality in patients who are treated within a universal healthcare system. Smoking, pelvic lymphadenectomy and receipt of adjuvant chemotherapy are independent prognostic factors for survival. Neoadjuvant chemotherapy continues to be under-utilized in Canada.